Market Overview

UPDATE: Jefferies Downgrades Cepheid to Hold on Persistent Volatility

Share:
Related CPHD
Mid-Afternoon Market Update: NASDAQ Down Over 1%; SkyWest Shares Jump On Earnings Beat
Mid-Day Market Update: Amazon Surges On Upbeat Results; ImmunoGen Shares Decline

In a report published on Friday, Jefferies analyst Brandon Couillard downgraded Cepheid (NASDAQ: CPHD) from Buy to Hold and maintained a price target of $38.00.

In the report, Jefferies noted, "CPHD has placed >1,000 systems in HBDC (high burden & developing countries) markets, which now account for ~25% of its global installed base. We forecast $45M & $57M (+26%) of HBDC revenues in 2013 & 2014, respectively, which conservatively factors a flat reagent annuity trend. With only ~60% of eligible countries on board, incremental HBDC-related revenues should continue to augment CPHD's core growth trajectory for the foreseeable future, though quarterly volatility is likely to persist until the program matures to scale."

Cepheid closed on Thursday at $36.62.

Latest Ratings for CPHD

DateFirmActionFromTo
Apr 2016BTIG ResearchUpgradesNeutralBuy
Feb 2016Stifel NicolausMaintainsBuy
Feb 2016BairdMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Brandon Couillard JefferiesAnalyst Color Downgrades Analyst Ratings

 

Related Articles (CPHD)

View Comments and Join the Discussion!